IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 265 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.49 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $122 | -84.7% | 26,791 | -76.4% | 0.01% | -88.1% |
| Q2 2023 | $798 | +127.4% | 113,329 | +97.3% | 0.10% | +215.6% |
| Q1 2023 | $351 | -99.9% | 57,448 | +30.8% | 0.03% | -23.8% |
| Q3 2022 | $421,000 | +184.5% | 43,907 | +226.6% | 0.04% | +147.1% |
| Q2 2022 | $148,000 | -62.6% | 13,443 | -35.2% | 0.02% | -61.4% |
| Q4 2021 | $396,000 | +89.5% | 20,744 | +144.3% | 0.04% | +76.0% |
| Q3 2021 | $209,000 | -59.7% | 8,490 | -48.2% | 0.02% | -57.6% |
| Q1 2021 | $519,000 | +45.0% | 16,388 | +25.6% | 0.06% | +9.3% |
| Q2 2020 | $358,000 | +53.6% | 13,051 | +55.2% | 0.05% | +45.9% |
| Q4 2019 | $233,000 | -15.9% | 8,409 | -71.1% | 0.04% | -17.8% |
| Q1 2019 | $277,000 | -1.8% | 29,085 | +16.2% | 0.04% | +15.4% |
| Q3 2018 | $282,000 | +112.0% | 25,033 | +46.0% | 0.04% | +77.3% |
| Q3 2017 | $133,000 | – | 17,143 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |